Disclosed herein is a technology for healing bone defects using bioactive silicate glass (BSG) and a 3D osteomimetic composite porous scaffold containing microspheres comprised of poly(lactide-co-glycolide) (PLGA).

Provided is a method of producing an osteoblast construct from iPS cells, the method including the steps of: (1) inducing formation of an embryoid body by subjecting undifferentiated iPS cells to non-adherent culture; (2) inducing differentiation of the iPS cells into mesodermal cells by subjecting the embryoid body of the iPS cells obtained in the step (1) to non-adherent culture; and (3) inducing differentiation into osteoblasts by subjecting the mesodermal cells of the iPS cells obtained in the step (2) to non-adherent culture, wherein the steps (1) and (2) are each performed using a culture vessel comprising a bottom surface and a circular side wall arranged upright on the bottom surface, the bottom surface having a plurality of depressed portions arranged independently of each other.

The present invention relates to a biomaterial comprising: —a membrane wound patch (a), made of a nanofibrous polymeric scaffold, —a hydrogel (b) including autologous or allogenic bone marrow-derived mesenchymal stem cells, and —a bone wound patch (c) being a nanofibrous scaffold made of polymers, wherein said scaffold has a surface coated with an interrupted coating made of multilayered droplets, said multilayered droplets being droplets composed of at least one layer pair consisting of a layer of polyanions and a layer of polycations, and wherein the bone wound patch (c) further comprises a bone growth factor; wherein the hydrogel (b) is included between the membrane wound patch (a) and the bone wound patch (c).

The present invention relates to a carrier composition for particulate and granular bone substitute materials which is a hydrogel comprising a mixture of ethylene oxide (EO)-propylene oxide (PO) block copolymers and silica nanoparticles embedded therein. The present invention further relates to a bone substitute material containing osteoconductive and/or osteoinductive particles or granules in addition to the novel carrier composition. Processes for producing the novel carrier composition and the novel bone substitute material are likewise provided in the context of the invention.

A viable disc regenerative composition has a micronized material of nucleus pulposus and a biological composition made from a mixture of mechanically selected allogeneic biologic material derived from bone marrow having non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components; and wherein the mixture is compatible with biologic function and further includes non-expanded whole cells. The biological composition is predisposed to demonstrate or support elaboration of active volume or spatial geometry consistent in morphology with that of disc tissue. The viable disc regenerative composition extends regenerative resonance that compliments or mimics disc tissue complexity.

A bone pore or void filling composition is described. The composition includes a mixture of: a type I collagen and/or a type I collagen-glycosaminoglycan coprecipitate; a blend of polyethylene glycol polymers having different molecular weights; a bone growth stimulator; and bioactive glass. A kit for containing the bone pore or void filling composition, and methods for using the composition to fill a bone pore or void are also described.

A bone void filler preparation system that includes a processing vessel, a processing cover, a bone void filler preparation container and tubing. The processing vessel has a recess formed therein. The processing vessel is adapted to receive bone marrow aspirate. The processing cover includes an outer wall, a central wall member and a connection port. The outer wall has an upper edge and a lower edge. The central wall member extends inwardly from the outer wall intermediate the upper and lower edges of the processing cover. The central wall member has an aperture formed therein. The central wall member has a downwardly directed portion that defines an air-retaining region. The air-retaining region is closer to the outer wall upper edge than the aperture. The connection port is operably connected to the aperture. The processing cover is movable in the processing cover recess. The bone void filler preparation container has an inlet portion and an outlet port. The bone void filler preparation container is adapted to receive a bone void filler matrix therein. The tubing fluidly connects the processing cover connection port and the bone void filler preparation container inlet port.

Disclosed is a method for manufacturing a 3D printing structure, the method including: producing a molded body by performing 3D printing on paste including printing powder in a coagulation bath including a hydrogel; hardening the molded body produced in the coagulation bath; and removing the hydrogel in the coagulation bath. A method for manufacturing a 3D printing structure, which is provided according to an aspect of the disclosure, does not require printing of a separate support, and thus it is possible to save time and costs. A post-processing process for removing a support is not required. Thus, a process is further simplified, and there is no risk of damage to a structure.

The present application relates to biomimetic three-dimensional (3D) scaffolds, constructs and methods of making the same. The three-dimensional scaffold can include a sacrificial internal cast and a durable external scaffold material, wherein the durable external scaffold material comprises a biocompatible material which completely surrounds the sacrificial internal cast and wherein the sacrificial internal cast be removed to yield a branching 3D network of hollow, vessel-like tubes that substantially mimics a native tissue or organ.

A method of making a bone matrix includes exposing a bone tissue to a solution including a surfactant and a protease; treating the bone tissue with an acid solution following exposing the bone tissue; and electrophoretically treating the acid treated bone tissue. A bone matrix has a DNA content of not greater than 0.1 micrograms per milligram sample and a modulus in a range of 180 kPa to 250 kPa.